EUCTR2009-012025-11-FR进行中（未招募）1 期
A double blind, randomized, placebo-controlled, parallel group, multicenter Phase 3 pivotal study to assess the safety and efficacy of 1mg/kg/day intravenous DP-b99 over 4 consecutive days versus placebo when initiated within nine hours of acute ischemic stroke onset - MACSI
D-Pharm Ltd.0 个研究点目标入组 770 人开始时间: 2010年1月11日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 770
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Male or females 18 to 85 years of age, inclusive
- •2. Have suffered an acute hemispheric ischemic stroke, defined as acute, focal, neurological deficit(s), secondary to a presumed vascular event, which must include at least one of the following components (as reflected by at least 1 point on any of the corresponding items of the NIHSS: 3, 9 or 11):
- •- Best Language
- •- Extinction and Inattention (formerly Neglect)
- •3. Have suffered the onset of an acute ischemic stroke that can be evaluated and treatment initiated within 9 hours after the onset of acute ischemic stroke symptoms. (Onset is defined as the time that the subject was last seen in a normal state, or bedtime for unwitnessed strokes occurring during sleep.)
- •4. Have at screening a NIHSS score of 10 to 16, inclusive
- •5. Have readily accessible peripheral venous access for clinical trial material (CTM) administration and blood sampling
- •6. Have the ability to understand the requirements of the study and be willing to provide written informed consent (IC) (as evidenced by signature on an informed consent document approved by an independent ethics committee (IEC), and agree to abide by the study restrictions and return for the required assessments. (In the event of incapacitated subjects, informed consent will be sought from a legally acceptable representative or by any other means as approved by the IRB or IEC).
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Have an intracerebral or subarachnoid hemorrhage per screening/baseline computerized tomography (CT) scan or susceptibility-weighted magnetic resonance imaging (MRI)
- •2. Be a candidate for thrombolytic therapy or have been treated with thrombolytic therapy for the current stroke
- •3. Be delirious, comatose or stuporous (a score of ?2 on item 1.a of the NIHSS) or demented, or having a mental impairment that in the investigator?s opinion renders the subject incapable to participate in the study
- •4. Have seizure(s) anytime from stroke onset to screening/baseline NIHSS evaluation
- •5. Have neurological or non-neurological comorbidities that in the investigator?s opinion may lead, independent of the current stroke, to further deterioration in the subject?s neurological status during the trial period, or may render the study?s neurological assessments inconclusive for the purpose of evaluating solely the stroke?s effects (e.g., metabolic encephalopathies, hemiplegic migraine, multiple sclerosis, central nervous system tumor, convulsive disorder, monocular blindness)
- •6. Be likely to undergo a procedure involving cardiopulmonary bypass during the study period
- •7. Have suffered a myocardial infarction in the last 90 days
- •8. Have any medical condition that in the investigator?s opinion may threaten the subject?s ability to complete the study (e.g., concurrent significant or life-threatening diseases, such as malignancies or end stage organ failure)
- •9. Have rapid spontaneous improvement of neurological signs during screening/baseline assessments
- •10. Have premorbid neurological deficits and functional limitations assessed by a pre-stroke Modified Rankin Scale score of > 1
- •11. Have suffered a stroke within 90 days of the screening/baseline assessments that is either diagnostically confirmed or assumed to be in the same cerebral territory as is the current acute stroke
- •12. Have either severe hypertension (systolic blood pressure (BP) >220 mm Hg or diastolic BP >120 mm Hg) or hypotension (systolic BP <90 mm Hg), as measured by at least 2 consecutive supine measurements taken 10 minutes apart immediately prior to first drug administration
- •13. Have significant current renal or hepatic disease(s): a serum creatinine concentration of >2.5 mg/dL; alanine aminotransferase (ALT), aspartate aminotransferase (AST), or gamma-glutamyl transferase (GGT) values that are three times greater the upper limit of normal (ULN)
- •14. Have a platelet count of <100,000/mm3 or for patients on oral anticoagulants at study entry, INR of >4
- •15. Be a female of childbearing potential (less than 2 years? postmenopausal or not surgically sterilized) who is not willing to use adequate and effective birth control measures for the duration of the trial. Effective birth control measures include hormonal contraception, a barrier method such as a diaphragm, intrauterine device (IUD) and/or condom with spermicide (IUD, diaphragm, condoms alone or the rhythm method are not considered reliable methods)
- •16. Have a positive urine pregnancy test at screening/baseline or be a lactating female
- •17. Be currently dependent on, or abusing, alcohol or one or more of the following: sympathomimetic amines (amphetamine-like), cannabis, cocaine, hallucinogens, inhalants, opioids, phencyclidine, sedatives and hypnotics
- •18. Have received an investigational drug or product or participated in an investigational drug study within a period of 30 days prior to receiving study medi
研究者
相似试验
进行中（未招募）
不适用
Study of Sativex for the Treatment of Cancer Related Pain.Pain in patients with advanced cancer who experience inadequate analgesia during optimized chronic opioid therapy.MedDRA version: 14.1Level: PTClassification code 10058019Term: Cancer painSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2009-016065-29-GBGW Pharma Ltd.380
进行中（未招募）
不适用
A double blind, randomized, placebo-controlled, parallel group, multicenter Phase 3 pivotal study to assess the safety and efficacy of 1mg/kg/day intravenous DP-b99 over 4 consecutive days versus placebo when initiated within nine hours of acute ischemic stroke onset - MACSIAcute Ischemic StrokeStroke is the most common neurologic disorder and is the third leading cause of death in developed countries, after myocardial infarction and cancer. Stroke is the second leading cause of neurological morbidity in the United States, Europe, and Japan. 67%- 81% of all stroke cases are ischemic strokes.MedDRA version: 12.0Level: LLTClassification code 10055221Term: Ischemic strokeEUCTR2009-012025-11-NLD-Pharm Ltd.770
进行中（未招募）
不适用
Study of Sativex for the Treatment of Cancer Related Pain.Pain in patients with advanced cancer, who experience inadequate analgesia during optimized chronic opioid therapy.MedDRA version: 14.1Level: PTClassification code 10058019Term: Cancer painSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2009-016064-36-LTGW Pharma Ltd380
进行中（未招募）
不适用
A double blind, randomized, placebo-controlled, parallel group, multicenter/multinational, efficacy and safety study of desloratadine 5 mg in the treatment of subjects with allergic rhinitis who meet the criteria for Persistent Allergic Rhinitis PER . - NDPersistent Allergic RhinitisMedDRA version: 8.1Level: LLTClassification code 10039085Term: Rhinitis allergicEUCTR2005-005450-45-ITSCHERING-PLOUGH800
进行中（未招募）
1 期
Study of Sativex for the Treatment of Cancer Related Pain.Pain in patients with advanced cancer, who experience inadequate analgesia during optimized chronic opoid therapy.MedDRA version: 14.1Level: PTClassification code 10058019Term: Cancer painSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2009-016065-29-DEGW Pharma Ltd.380